{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypercholesterolaemia-familial/management/adults-with-homozygous-fh/","result":{"pageContext":{"chapter":{"id":"2f9228e9-d4af-55d1-937d-74e9c83e418e","slug":"adults-with-homozygous-fh","fullItemName":"Scenario: Adults with homozygous FH","depth":2,"htmlHeader":"<!-- begin field 0aa68ddc-2c03-4b1e-a772-6dde7d50ddbb --><h2>Scenario: Management of adults with homozygous familial hypercholesterolaemia</h2><!-- end field 0aa68ddc-2c03-4b1e-a772-6dde7d50ddbb -->","summary":"Covers the management of adults with homozygous FH confirmed by a specialist.","htmlStringContent":"<!-- begin item 5d7f12af-4e40-454a-bfe0-4a5f03f06824 --><!-- begin field 775c3ca3-00ae-45a9-9672-acd900ade2df --><p>From age 15 years onwards.</p><!-- end field 775c3ca3-00ae-45a9-9672-acd900ade2df --><!-- end item 5d7f12af-4e40-454a-bfe0-4a5f03f06824 -->","topic":{"id":"e1e436f3-28ca-5b97-8fd7-0156f61bfd7c","topicId":"030641a4-5f0a-4edf-a3ac-c21903c0095e","topicName":"Hypercholesterolaemia - familial","slug":"hypercholesterolaemia-familial","lastRevised":"Last revised in September 2020","chapters":[{"id":"23ce1270-bfbc-5ded-ab6d-c230787a3f98","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1ac01f09-287f-5fd1-a1a5-3392235af19a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a92fc8a9-1061-5c02-bfff-d5f934ffdb53","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"93e2888f-005e-50e1-8f04-9c8023c43019","slug":"changes","fullItemName":"Changes"},{"id":"4cd7461b-b74a-5b4a-bbf9-499684c190d6","slug":"update","fullItemName":"Update"}]},{"id":"ebac4860-8279-5daa-8053-2376a8a9d71d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"18209ebb-2e72-5f12-879c-4cac6c4a4a74","slug":"goals","fullItemName":"Goals"},{"id":"db603b52-871f-5820-9fbc-8fa05bcd0c1c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"107217fb-afa8-59f5-b492-20a089b4ff48","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55a1140b-b028-5056-9c88-5836bc15dd3b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ef31a150-3669-5487-b7f5-e19d13bf639e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"00bd8dc2-4dee-5ba6-a759-82c99a58cd4d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2cc20b8e-5159-51e2-b31b-9d3f16bcff36","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ec5f41d9-1fa0-53f1-aaee-0b37d62682af","slug":"definition","fullItemName":"Definition"},{"id":"687776fd-3a40-5dcf-ada0-1e58ff0f3128","slug":"causes","fullItemName":"Causes"},{"id":"cb1847cd-3321-5104-a764-beaf8c58397c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"63b1cca3-87f7-5577-af56-fb3b38977e30","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"13588941-b46f-5306-a752-0527c4458410","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4be7f4e2-6458-5112-948b-50b0e98bbb7a","slug":"identification","fullItemName":"Identification"},{"id":"343de6bd-ed4d-5fcc-b7d7-7ca1565daf0d","slug":"assessment-diagnosis","fullItemName":"Assessment and diagnosis"}]},{"id":"13ac6594-5e56-502b-96f4-2f848eb59c83","fullItemName":"Management","slug":"management","subChapters":[{"id":"2349db0e-12d5-5ff8-8e14-2e885307ad42","slug":"adults-with-heterozygous-fh","fullItemName":"Scenario: Adults with heterozygous FH"},{"id":"2f9228e9-d4af-55d1-937d-74e9c83e418e","slug":"adults-with-homozygous-fh","fullItemName":"Scenario: Adults with homozygous FH"},{"id":"c8ba3d52-d1bc-5e22-a366-a32ab938db00","slug":"children-young-people-with-fh","fullItemName":"Scenario: Children and young people with FH"}]},{"id":"323963cd-05be-519c-a523-3922e41f11f0","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c555b9e-f39b-567f-89ff-c983ab785087","slug":"statins-atorvastatin-rosuvastatin-simvastatin","fullItemName":"Statins (atorvastatin, rosuvastatin, and simvastatin)"},{"id":"8007ba2c-d902-5e52-9fb3-1aedd9470650","slug":"ezetimibe","fullItemName":"Ezetimibe"}]},{"id":"189143bc-5ae2-58d6-83ae-e0cd9bc01ee6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"efd82555-8ecb-5170-be69-2e7390295832","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"652a4e82-a231-5cb4-8c7c-563ca0f43bbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"2be02b62-6acf-5570-854e-e6dcbfb36426","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7d6217e2-3ab0-516c-97eb-53f4083e8805","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2ce56158-d459-5b28-8343-7b6d776dc77a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3f7dd940-f042-5f4d-8968-a8002af95e8d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ca7fcd28-909d-579e-8783-9249cd67764f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"13ac6594-5e56-502b-96f4-2f848eb59c83","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"d60f4663-0e91-597c-8259-a676822931c0","slug":"management-of-adults-with-confirmed-homozygous-fh","fullItemName":"Management of adults with confirmed homozygous FH","depth":3,"htmlHeader":"<!-- begin field 8f4fad25-0aa8-40b1-a56b-9145402fcac4 --><h3>How should I manage an adult with confirmed homozygous familial hypercholesterolaemia?</h3><!-- end field 8f4fad25-0aa8-40b1-a56b-9145402fcac4 -->","summary":null,"htmlStringContent":"<!-- begin item 0075da7b-daaa-49df-9b01-5a18a248088b --><!-- begin field c7381c06-efbf-41ee-81a8-a2e4f3f5636f --><ul><li><strong>Provide written information on FH, for example:</strong> <ul><li>HEART UK (<a data-hyperlink-id=\"ac1084fb-d0a1-422d-9b20-a98d002f8f2b\" href=\"http://www.heartuk.org.uk/\">www.heartuk.org.uk</a>) has <a data-hyperlink-id=\"6a7ded54-734c-45a5-988e-aa0200c1c238\" href=\"https://www.heartuk.org.uk/genetic-conditions/homozygous-familial-hypercholesterolaemia-hofh\">online information</a> for people with homozygous FH. </li></ul></li><li><strong>Ensure that all adults with confirmed homozygous familial hypercholesterolaemia (FH) are managed in secondary care by a specialist with expertise in FH.</strong><ul><li>Specialist management may include:<ul><li>Drug treatment with bile acid sequestrants (resins), nicotinic acid, and/or fibrates (usually in addition to statins and/or ezetimibe).</li><li>Low-density lipoprotein (LDL) apheresis, which involves removal of blood (usually via an arterio-venous fistula) for treatment to clear LDL cholesterol.</li><li>Liver transplant.</li></ul></li></ul></li></ul><!-- end field c7381c06-efbf-41ee-81a8-a2e4f3f5636f --><!-- end item 0075da7b-daaa-49df-9b01-5a18a248088b -->","subChapters":[{"id":"1e74ad44-24df-5585-8b70-eb4b3ea91e88","slug":"basis-for-recommendation-8cb","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 506deb3b-9bed-46eb-b9b4-065e9728ddb6 --><h4>Basis for recommendation</h4><!-- end field 506deb3b-9bed-46eb-b9b4-065e9728ddb6 -->","summary":null,"htmlStringContent":"<!-- begin item 8cb4cfd2-6389-45a3-82da-79ef5afd9e96 --><!-- begin field 62dc8d9b-46f6-4f31-b629-9af5094ef193 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Identification and management of familial hypercholesterolaemia (Full guideline) </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">National Collaborating Centre for Primary Care, 2017</a>] and <em>Familial hypercholesterolaemia: identification and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2017a</a>]<em>.</em></p><ul><li>NICE recommends that drug treatment for adults with homozygous familial hypercholesterolaemia (FH) should be undertaken within a specialist centre.</li><li>The information on the specialist management options is largely taken from the NICE guideline <em><em>Identification and management of familial hypercholesterolaemia (Full guideline) </em></em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">National Collaborating Centre for Primary Care, 2017</a>]. Additional information on low-density lipoprotein (LDL) apheresis is taken from a systematic review on the effects of LDL apheresis on cardiovascular pathophysiology and clinical outcomes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Thompsen and Thompson, 2006</a>].</li></ul><!-- end field 62dc8d9b-46f6-4f31-b629-9af5094ef193 --><!-- end item 8cb4cfd2-6389-45a3-82da-79ef5afd9e96 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}